ReviewInternational journal of laboratory hematology2022
Diagnosis and treatment of thrombotic microangiopathy.
Review in International journal of laboratory hematology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 66 citations in OpenAlex.
- Comparison between effectiveness and safety of plasma therapy and complement inhibitors for the treatment of atypical hemolytic uremic syndrome: a systematic review and meta-analysis of real-world data.Pediatric nephrology (Berlin, Germany) · 2026Pooled it
- Immune Thrombotic Thrombocytopenic Purpura Presenting as an Acute Stroke Mimic in a Young Pakistani Man.Cureus · 2026Article
- A rapid ADAMTS13 activity assay using a portable readout device.Blood vessels, thrombosis & hemostasis · 2026Article
- Delayed Recognition of Thrombotic Thrombocytopenic Purpura Following Platelet Transfusion: A Clinical Pitfall.Clinical case reports · 2026Article
- Fatal snakebite-induced thrombotic microangiopathy with incidental rheumatic heart disease: an autopsy case report.Forensic science, medicine, and pathology · 2026Article
- Article
- From dog bite to dialysis: complement-mediated haemolytic uraemic syndrome .BMJ case reports · 2026Article
- Establishing a rapid-response multidisciplinary service for thrombotic microangiopathies using a model of improvement framework: perspectives from a Brazilian quaternary hospital.Frontiers in medicine · 2026Article
- Thrombotic microangiopathy associated with mantle cell lymphoma: a case report.BMC nephrology · 2025Article
- Pathogenic cytokines in thrombotic microangiopathies: molecular insights and therapeutic targets.Molecular medicine (Cambridge, Mass.) · 2025Review
- Diagnostic and Prognostic Evaluation of Disseminated Intravascular Coagulation Using the Disseminated Intravascular Coagulation Index.Journal of clinical medicine · 2025Article
- Emerging Thrombotic Disorders Associated with Virus-Based Innovative Therapies: From VITT to AAV Gene Therapy-Related Thrombotic Microangiopathy.Thrombosis and haemostasis · 2025Review
- Proteasome inhibitor-associated thrombotic microangiopathy: a real-world retrospective and pharmacovigilance database analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- Thrombotic Microangiopathy (TMA) in a Heart Transplant Patient: A Complex Clinical-Pathologic Dilemma.Case reports in medicine · 2025Article
- A novel heterozygous mutation in the gelsolin gene causes Finnish gelsolin amyloidosis associated with nephropathy and thrombotic microangiopathy.Archives of medical science : AMS · 2025Article
- Detection of Thrombosis Using Soluble C-Type Lectin-like Receptor-2 with D-Dimer Level and Platelet Count.Journal of clinical medicine · 2024Article
- Deciphering Complexity: Atypical Hemolytic Uremic Syndrome Unraveled in the Wake of Elective Hip Arthroplasty.Cureus · 2024Article
- The Phenomenon of Thrombotic Microangiopathy in Cancer Patients.International journal of molecular sciences · 2024Review
- Cancer-Associated Thrombotic Microangiopathy: Literature Review and Report of Five Cases.Life (Basel, Switzerland) · 2024Article
- Renal Involvement in Thrombotic Thrombocytopenic Purpura: Is It Time to Challenge the Old Paradigm?Cureus · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thrombotic microangiopathy (TMA) is characterized by thrombocytopenia, microangiopathic haemolytic anaemia and end organ damage. TMAs have varying underlying pathophysiology and can therefore present with an array of clinical presentations. Renal involvement is common as the kidney is particularly susceptible to the endothelial damage and microvascular occlusion. TMAs require rapid assessment, diagnosis, and commencement of appropriate treatment due to the high morbidity and mortality associated with them. Ground-breaking research into the pathogenesis of TMAs over the past 20 years has driven the successful development of targeted therapeutics revolutionizing patient outcomes. This review outlines the clinical presentations, pathogenesis, diagnostic tests and treatments for TMAs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.